{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046867","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.059828+00:00","generated_at":"2026-05-30T01:58:32.964767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350","bullets":["Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.","Cash and marketable securities $62.7M; expected to fund operations into H2 2026.","Phase 1 MAD study of OV329 progressing; plans to add cohorts for higher dosing; topline data in 2025.","Regulatory application for Phase 1 trial of OV350 (KCC2 direct activator) expected in Q4 2024; first-in-human Q1 2025.","Pause of Phase 2 study of OV888/GV101 in CCM to incorporate competitor trial insights; ROCK2 programs continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046867","json":"https://secwatch.observer/filing/0001628280-24-046867.json","markdown":"https://secwatch.observer/filing/0001628280-24-046867.md","text":"https://secwatch.observer/filing/0001628280-24-046867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/0001628280-24-046867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/ovid-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:58:32.964767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}